Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
PhD Kevin E Kip, PharmD Erin K Mccreary, MBA Kevin Collins, MS; Tami E Minnier, MD Graham M Snyder, MS William Garrard, PhD; Jeffrey C Mckibben, MS; Donald M Yealy, MD Christopher W Seymour, MD, MSc David T Huang, MD, MPH J Ryan Bariola, MD Mark Schmidhofer, MD Richard J Wadas, MD Derek C Angus, MD, MPH Paula L Kip, PhD Oscar C Marroquin
Annals of Internal Medicine, doi:10.7326/m22-1286
Background: Treatment guidelines and U.S. Food and Drug Administration emergency use authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients with mild to moderate COVID-19 changed frequently as different SARS-CoV-2 variants emerged. Objective: To evaluate whether early outpatient treatment with mAbs, overall and by mAb product, presumed SARS-CoV-2 variant, and immunocompromised status, is associated with reduced risk for hospitalization or death at 28 days. Design: Hypothetical pragmatic randomized trial from observational data comparing mAb-treated patients with a propensity score-matched, nontreated control group. Setting: Large U.S. health care system. Participants: High-risk outpatients eligible for mAb treatment under any EUA with a positive SARS-CoV-2 test result from 8 December 2020 to 31 August 2022. Intervention: Single-dose intravenous mAb treatment with bamlanivimab, bamlanivimab-etesevimab, sotrovimab, bebtelovimab, or intravenous or subcutaneous casirivimab-imdevimab administered within 2 days of a positive SARS-CoV-2 test result. Measurements: The primary outcome was hospitalization or death at 28 days among treated patients versus a nontreated control group (no treatment or treatment ≥3 days after SARS-CoV-2 test date).
Results: The risk for hospitalization or death at 28 days was 4.6% in 2571 treated patients and 7.6% in 5135 nontreated control patients (risk ratio [RR], 0.61 [95% CI, 0.50 to 0.74]). In sensitivity analyses, the corresponding RRs for 1-and 3-day treatment grace periods were 0.59 and 0.49, respectively. In subgroup analyses, those receiving mAbs when the Alpha and Delta variants were presumed to be predominant had estimated RRs of 0.55 and 0.53, respectively, compared with 0.71 for the Omicron variant period. Relative risk estimates for individual mAb products all suggested lower risk for hospitalization or death. Among immunocompromised patients, the RR was 0.45 (CI, 0.28 to 0.71). Limitations: Observational study design, SARS-CoV-2 variant presumed by date rather than genotyping, no data on symptom severity, and partial data on vaccination status.
Conclusion: Early mAb treatment among outpatients with COVID-19 is associated with lower risk for hospitalization or death for various mAb products and SARS-CoV-2 variants.
The bottom section depicts 1:2 propensity score matching of treated and nontreated patients. mAb = monoclonal antibody.
References
Ahmed, Quadeer, Mckay, Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies, Viruses,
doi:10.3390/v12030254Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat,
doi:10.1002/pst.433Bariola, Mccreary, Wadas, Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection, Open Forum Infect Dis,
doi:10.1093/ofid/ofab254Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Cox, Peacock, Harvey, COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat Rev Microbiol,
doi:10.1038/s41579-022-00809-7Dryden-Peterson, Kim, Joyce, Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system, Open Forum Infect Dis,
doi:10.1093/ofid/ofac565Focosi, Mcconnell, Casadevall, The Omicron variant of concern: diversification and convergent evolution in spike protein, and escape from anti-spike monoclonal antibodies, Drug Resist Updat,
doi:10.1016/j.drup.2022.100882Food, not currently authorized for emergency use in the U
Gupta, Gonzalez-Rojas, Juarez, Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2022.2832Gupta, Vemula, Donde, In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1751300Haidar, Agha, Bilderback, Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS), Clin Infect Dis,
doi:10.1093/cid/ciac103Huang, Mccreary, Bariola, Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.20957Lewnard, Hong, Patel, Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,
doi:10.1038/s41591-022-01887-zLin, Hung, Lai, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials, J Med Virol,
doi:10.1002/jmv.27623Mccreary, Bariola, Minnier, The comparative effectiveness of COVID-19 monoclonal antibodies: a learning health system randomized clinical trial, Contemp Clin Trials,
doi:10.1016/j.cct.2022.106822Mccreary, Bariola, Wadas, Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.6920Mccreary, Kip, Bariola, A learning health system approach to the COVID-19 pandemic: system-wide changes in clinical practice and 30-day mortality among hospitalized patients, Learn Health Sys,
doi:10.1002/lrh2.10304Mccreary, Kip, Collins, Evaluation of bebtelovimab for treatment of Covid-19 during the SARS-CoV-2 Omicron variant era, Open Forum Infect Dis,
doi:10.1093/ofid/ofac517Nagler, Horwitz, Jones, The impact of COVID-19 monoclonal antibodies on clinical outcomes: a retrospective cohort study, Am J Health Syst Pharm,
doi:10.1093/ajhp/zxac295Nathan, Shawa, De, Torre, A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2, Infect Dis Ther,
doi:10.1007/s40121-021-00515-6Reitz, Seymour, Vates, Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients, BMJ Open,
doi:10.1136/bmjopen-2020-037690Rosenbaum, Db, The central role of the propensity score in observational studies for causal effects, Biometrika,
doi:10.1093/biomet/70.1.41Services, COVID-19 Monoclonal Antibodies
Stokes, Zambrano, Anderson, Coronavirus disease 2019 case surveillance -United States, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm6924e2Tao, Tzou, Pond, Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis, Microbiol Spectr,
doi:10.1128/spectrum.00926-22Wang, Casner, Nair, A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses, Emerg Microbes Infect,
doi:10.1080/22221751.2021.2011623Weinreich, Sivapalasingam, Norton, Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2108163Widyasari, Kim, A review of the currently available antibody therapy for the treatment of coronavirus disease 2019 (COVID-19), Antibodies,
doi:10.3390/antib12010005Wynia, Beaty, Bennett, Real-world evidence of neutralizing monoclonal antibodies for preventing hospitalization and mortality in COVID-19 outpatients, Chest,
doi:10.1016/j.chest.2022.10.020{ 'indexed': {'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T19:13:42Z', 'timestamp': 1712690022806},
'reference-count': 33,
'publisher': 'American College of Physicians',
'issue': '4',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 4]]},
'DOI': '10.7326/m22-1286',
'type': 'journal-article',
'created': {'date-parts': [[2023, 4, 3]], 'date-time': '2023-04-03T21:00:29Z', 'timestamp': 1680555629000},
'page': '496-504',
'source': 'Crossref',
'is-referenced-by-count': 17,
'title': 'Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19',
'prefix': '10.7326',
'volume': '176',
'author': [ { 'given': 'Kevin E.',
'family': 'Kip',
'sequence': 'first',
'affiliation': [ { 'name': 'Clinical Analytics, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., O.C.M.)'}]},
{ 'given': 'Erin K.',
'family': 'McCreary',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Department of Medicine, '
'University of Pittsburgh School of Medicine, Pittsburgh, '
'Pennsylvania (E.K.M., G.M.S., J.R.B.)'}]},
{ 'given': 'Kevin',
'family': 'Collins',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Analytics, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., O.C.M.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-6149-0424',
'authenticated-orcid': False,
'given': 'Tami E.',
'family': 'Minnier',
'sequence': 'additional',
'affiliation': [ { 'name': 'Wolff Center, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (T.E.M., P.L.K.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-5562-8880',
'authenticated-orcid': False,
'given': 'Graham M.',
'family': 'Snyder',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Department of Medicine, '
'University of Pittsburgh School of Medicine, Pittsburgh, '
'Pennsylvania (E.K.M., G.M.S., J.R.B.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-5141-6239',
'authenticated-orcid': False,
'given': 'William',
'family': 'Garrard',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Analytics, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., O.C.M.)'}]},
{ 'given': 'Jeffrey C.',
'family': 'McKibben',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Analytics, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., O.C.M.)'}]},
{ 'given': 'Donald M.',
'family': 'Yealy',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Emergency Medicine, University of Pittsburgh '
'School of Medicine, Pittsburgh, Pennsylvania (D.M.Y., R.J.W.)'}]},
{ 'given': 'Christopher W.',
'family': 'Seymour',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Critical Care Medicine, University of Pittsburgh '
'School of Medicine, Pittsburgh, Pennsylvania (C.W.S., D.C.A.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-7649-1633',
'authenticated-orcid': False,
'given': 'David T.',
'family': 'Huang',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Emergency Medicine and Department of Critical Care '
'Medicine, University of Pittsburgh School of Medicine, '
'Pittsburgh, Pennsylvania (D.T.H.)'}]},
{ 'given': 'J. Ryan',
'family': 'Bariola',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Department of Medicine, '
'University of Pittsburgh School of Medicine, Pittsburgh, '
'Pennsylvania (E.K.M., G.M.S., J.R.B.)'}]},
{ 'given': 'Mark',
'family': 'Schmidhofer',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Cardiology, Department of Medicine, University of '
'Pittsburgh School of Medicine, Pittsburgh, Pennsylvania '
'(M.S.).'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-6152-9990',
'authenticated-orcid': False,
'given': 'Richard J.',
'family': 'Wadas',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Emergency Medicine, University of Pittsburgh '
'School of Medicine, Pittsburgh, Pennsylvania (D.M.Y., R.J.W.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-7026-5181',
'authenticated-orcid': False,
'given': 'Derek C.',
'family': 'Angus',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Critical Care Medicine, University of Pittsburgh '
'School of Medicine, Pittsburgh, Pennsylvania (C.W.S., D.C.A.)'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-8337-4777',
'authenticated-orcid': False,
'given': 'Paula L.',
'family': 'Kip',
'sequence': 'additional',
'affiliation': [ { 'name': 'Wolff Center, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (T.E.M., P.L.K.)'}]},
{ 'given': 'Oscar C.',
'family': 'Marroquin',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Analytics, University of Pittsburgh Medical Center, '
'Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., '
'O.C.M.)'}]}],
'member': '4285',
'reference': [ {'key': 'r5-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2108163'},
{'key': 'r7-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.1225'},
{'key': 'r8-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab254'},
{'key': 'r12-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofac517'},
{'key': 'r13-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofac565'},
{ 'key': 'r14-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2022.6920'},
{'key': 'r15-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cct.2022.106822'},
{ 'key': 'r16-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2022.20957'},
{ 'key': 'r17-M221286',
'doi-asserted-by': 'crossref',
'unstructured': 'McCreary EK, Kip KE, Bariola JR, et al. A learning health system '
'approach to the COVID-19 pandemic: system-wide changes in clinical '
'practice and 30-day mortality among hospitalized patients. Learn Health '
'Sys. 2022;6:e10304. doi:10.1002/lrh2.10304',
'DOI': '10.1101/2021.08.26.21262661'},
{'key': 'r18-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmjopen-2020-037690'},
{ 'key': 'r23-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/00273171.2011.568786'},
{ 'key': 'r24-M221286',
'doi-asserted-by': 'crossref',
'unstructured': 'Rosenbaum PR, Rubin DB. The central role of the propensity score in '
'observational studies for causal effects. Biometrika. 1983;70:41-55. '
'doi:10.1093/biomet/70.1.41',
'DOI': '10.1093/biomet/70.1.41'},
{'key': 'r25-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/pst.433'},
{'key': 'r26-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chest.2022.10.020'},
{'key': 'r27-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ajhp/zxac295'},
{'key': 'r28-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2029849'},
{'key': 'r29-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2022.2832'},
{'key': 'r30-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27623'},
{ 'key': 'r31-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1158/2159-8290.CD-20-0516'},
{'key': 'r32-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm6924e2'},
{'key': 'r33-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac103'},
{ 'key': 'r34-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/07391102.2020.1751300'},
{'key': 'r35-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v12030254'},
{ 'key': 'r36-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1021/acs.jmedchem.0c00606'},
{'key': 'r37-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/antib12010005'},
{'key': 'r38-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2003138117'},
{'key': 'r39-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2571-7'},
{'key': 'r40-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-021-00515-6'},
{'key': 'r41-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-022-00809-7'},
{'key': 'r42-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/spectrum.00926-22'},
{'key': 'r43-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.drup.2022.100882'},
{ 'key': 'r44-M221286',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/22221751.2021.2011623'},
{'key': 'r46-M221286', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-022-01887-z'}],
'container-title': 'Annals of Internal Medicine',
'original-title': [],
'language': 'en',
'deposited': { 'date-parts': [[2023, 4, 17]],
'date-time': '2023-04-17T21:02:01Z',
'timestamp': 1681765321000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.acpjournals.org/doi/10.7326/M22-1286'}},
'subtitle': ['A Cohort Study'],
'short-title': [],
'issued': {'date-parts': [[2023, 4]]},
'references-count': 33,
'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2023, 4]]}},
'alternative-id': ['10.7326/M22-1286'],
'URL': 'http://dx.doi.org/10.7326/M22-1286',
'relation': {},
'ISSN': ['0003-4819', '1539-3704'],
'subject': ['General Medicine', 'Internal Medicine'],
'container-title-short': 'Ann Intern Med',
'published': {'date-parts': [[2023, 4]]}}
